Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 10,525 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 1 Interventional

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294
View directory record Official record
Conditions
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Interventions
Navitoclax, Venetoclax, Decitabine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 1 Interventional

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891
View directory record Official record
Conditions
High-Grade Glioma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Palo Alto, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional

Neurofeedback in Decreasing Acute Radiotherapy-Induced Pain in Patients With Head and Neck Cancer

NCT02543320
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
LORETA Neurofeedback Training, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241
View directory record Official record
Conditions
IgG4 Related Disease
Interventions
Obexelimab, Placebo
Drug · Other
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Stanford, California • Naples, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional

Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder

NCT03184454
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Medtronic Percept Deep Brain Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Charlestown, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 1 Interventional

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

NCT05775094
View directory record Official record
Conditions
Osteoporosis, Multiple Myeloma
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497
View directory record Official record
Conditions
IgG4 Related Disease
Interventions
Inebilizumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting No phase listed Observational

Eye Plaque Brachytherapy for Ocular Melanoma

NCT06432660
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Data collection
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Addition of Steroids on Duration of Analgesia

NCT04126824
View directory record Official record
Conditions
Uterine Fibroids, Adenomyosis
Interventions
Triamcinolone, Bupivacaine, Iohexol contrast
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Westwood, Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting No phase listed Observational

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

NCT02808780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
16
States / cities
Murrieta, California • Rialto, California • Ventura, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional

GaitBetter: Motor and Cognitive Training for Gait Rehabilitation and Falls Prevention in Stroke Survivors.

NCT04625127
View directory record Official record
Conditions
Stroke, Gait, Hemiplegic, Hemiplegia
Interventions
Treadmill gait training with GaitBetter, Treadmill gait training with GaitBetter + Standard of care, Standard of care
Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional

ColoSeal™ ICD System Anastomotic Protection Pivotal Study

NCT07429110
View directory record Official record
Conditions
Rectal Cancer Surgery
Interventions
ColoSeal ICD System, Protective Diverting Ostomy
Device · Procedure
Lead sponsor
Averto Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Orlando, Florida • Weston, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Early Phase 1 Interventional

A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05336266
View directory record Official record
Conditions
Pancreas Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
Ketorolac Tromethamine
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility and Fidelity of a Gross Motor-based Physical Activity Intervention on Cognition in Preschool-age Children

NCT05949866
View directory record Official record
Conditions
Activity, Motor
Interventions
Movement and Cognition Intervention Group, Health Tracker Group (Control Group)
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
3 Years to 5 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 2 Interventional

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520
View directory record Official record
Conditions
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
Interventions
SGN-35
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT02873962
View directory record Official record
Conditions
Peritoneal Cancer, Ovarian Cancer, Fallopian Tube Cancer
Interventions
Bevacizumab, Nivolumab, Rucaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

NCT05119569
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Fullerton, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 3 Interventional Results available

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

NCT03057054
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia, Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Lactobacillus plantarum strain 299, Lactobacillus plantarum strain 299v, Placebo Administration
Procedure · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Development of a Patient-Reported Outcome Measure to Assess Recovery After Abdominal Surgery

NCT03461497
View directory record Official record
Conditions
Abdominal Surgery
Interventions
Not listed
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 3 Interventional

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Recreational Basketball to Increase Participation in Diabetes Prevention

NCT05066542
View directory record Official record
Conditions
Type 2 Diabetes, PreDiabetes
Interventions
NDPP + Basketball (BB), NDPP Standard of Care SOC
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 44 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Not applicable Interventional

Cervical Plexus Hydrodissection With D5W for PTSD

NCT04421573
View directory record Official record
Conditions
PTSD
Interventions
BCPHD with D5W, Waiting period with usual care
Procedure
Lead sponsor
Dr. Dean Reeves Clinic
Other
Eligibility
19 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Lexington, Kentucky • Portland, Oregon • Tigard, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 9, 2026, 10:06 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis, Olaparib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 9, 2026, 10:06 AM EST